• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

蛋白酶体活性的潜在别构调节剂。

Potential allosteric modulators of the proteasome activity.

机构信息

Faculty of Chemistry, University of Gdansk, Sobieskiego 18, Gdansk 80-952, Poland.

出版信息

Biopolymers. 2010 May;93(5):481-95. doi: 10.1002/bip.21381.

DOI:10.1002/bip.21381
PMID:20091677
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2882558/
Abstract

Proteasome, consisting of a tube-shaped proteolytic core particle and attached to it regulatory modules, is a multifunctional enzymatic complex essential for the ubiquitin-proteasome metabolic pathway. Due to its immense involvement in regulation of cellular physiology, the proteasome is an acknowledged anticancer drug target and potential target to treat inflammatory or degenerative diseases. So far, competitive inhibitors of the core particle gain most consideration as drugs. We postulate that noncompetitively-acting small-molecule compounds would provide excellent means to precisely regulate actions of the proteasome. In this study, we evaluated five short peptides based on sequences of two proteins known to interact with the core proteasome: HIV-1 Tat and PA28/REG activator. We performed Circular Dichroism (CD), Fourier Transformed Infrared Spectroscopy (FTIR), and Nuclear Magnetic Resonance (NMR) analysis, supplemented by MD simulations, and tested influence of the peptides on performance of the core particle active sites and functioning of regulatory modules. We found that PP2-containing Tat peptides are noncompetitive inhibitors of the core, interfering with the actions of PA28alphabeta activator. In addition, at low concentrations the turn-prone Tat2 is able to activate the latent core. The random coil-structured PA28-derived peptides display only weak or nondetectable direct effects on the core activities, exhibiting, however, a positive cooperation with activity-enhancing actions of PA28alphabeta.

摘要

蛋白酶体由一个管状的蛋白酶核心颗粒和与其相连的调节模块组成,是泛素蛋白酶体代谢途径中必不可少的多功能酶复合物。由于其在调节细胞生理过程中具有巨大的作用,蛋白酶体是公认的抗癌药物靶点,也是治疗炎症或退行性疾病的潜在靶点。到目前为止,核心颗粒的竞争性抑制剂作为药物得到了最多的关注。我们假设非竞争性作用的小分子化合物将为精确调节蛋白酶体的作用提供极好的手段。在这项研究中,我们评估了基于两种已知与核心蛋白酶体相互作用的蛋白质(HIV-1 Tat 和 PA28/REG 激活剂)序列的五个短肽。我们进行了圆二色性(CD)、傅里叶变换红外光谱(FTIR)和核磁共振(NMR)分析,辅之以 MD 模拟,并测试了这些肽对核心颗粒活性部位性能和调节模块功能的影响。我们发现含有 PP2 的 Tat 肽是核心的非竞争性抑制剂,干扰了 PA28alphabeta 激活剂的作用。此外,在低浓度下,易形成转角的 Tat2 能够激活潜伏的核心。随机卷曲结构的 PA28 衍生肽对核心活性仅显示出微弱或不可检测的直接影响,但与 PA28alphabeta 增强活性的作用具有正协同作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7daa/2882558/934a412473e4/nihms188539f10.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7daa/2882558/06e316a7aa79/nihms188539f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7daa/2882558/221d14137c01/nihms188539f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7daa/2882558/4930cc591ae2/nihms188539f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7daa/2882558/11ecc568c0c9/nihms188539f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7daa/2882558/001889a6380e/nihms188539f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7daa/2882558/7e69b60bc81d/nihms188539f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7daa/2882558/1d9c1bb3057a/nihms188539f7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7daa/2882558/793d8a0bf4ff/nihms188539f8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7daa/2882558/8a43b7c34afa/nihms188539f9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7daa/2882558/934a412473e4/nihms188539f10.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7daa/2882558/06e316a7aa79/nihms188539f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7daa/2882558/221d14137c01/nihms188539f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7daa/2882558/4930cc591ae2/nihms188539f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7daa/2882558/11ecc568c0c9/nihms188539f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7daa/2882558/001889a6380e/nihms188539f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7daa/2882558/7e69b60bc81d/nihms188539f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7daa/2882558/1d9c1bb3057a/nihms188539f7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7daa/2882558/793d8a0bf4ff/nihms188539f8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7daa/2882558/8a43b7c34afa/nihms188539f9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7daa/2882558/934a412473e4/nihms188539f10.jpg

相似文献

1
Potential allosteric modulators of the proteasome activity.蛋白酶体活性的潜在别构调节剂。
Biopolymers. 2010 May;93(5):481-95. doi: 10.1002/bip.21381.
2
Dissecting a role of a charge and conformation of Tat2 peptide in allosteric regulation of 20S proteasome.剖析Tat2肽的电荷和构象在20S蛋白酶体变构调节中的作用。
J Pept Sci. 2014 Aug;20(8):649-56. doi: 10.1002/psc.2642. Epub 2014 May 13.
3
Interplay between Structure and Charge as a Key to Allosteric Modulation of Human 20S Proteasome by the Basic Fragment of HIV-1 Tat Protein.结构与电荷之间的相互作用是HIV-1 Tat蛋白碱性片段对人20S蛋白酶体变构调节的关键。
PLoS One. 2015 Nov 17;10(11):e0143038. doi: 10.1371/journal.pone.0143038. eCollection 2015.
4
PA28αβ reduces size and increases hydrophilicity of 20S immunoproteasome peptide products.PA28αβ可减小20S免疫蛋白酶体肽产物的大小并增加其亲水性。
Chem Biol. 2014 Apr 24;21(4):470-480. doi: 10.1016/j.chembiol.2014.02.006. Epub 2014 Mar 13.
5
New Peptide-Based Pharmacophore Activates 20S Proteasome.新型基于肽的药效团激活 20S 蛋白酶体。
Molecules. 2020 Mar 22;25(6):1439. doi: 10.3390/molecules25061439.
6
The RTP site shared by the HIV-1 Tat protein and the 11S regulator subunit alpha is crucial for their effects on proteasome function including antigen processing.HIV-1反式激活蛋白(Tat蛋白)与11S调节亚基α所共有的RTP位点,对于它们影响包括抗原加工在内的蛋白酶体功能至关重要。
J Mol Biol. 2002 Nov 1;323(4):771-82. doi: 10.1016/s0022-2836(02)00998-1.
7
Proline- and Arginine-Rich Peptides as Flexible Allosteric Modulators of Human Proteasome Activity.脯氨酸和精氨酸丰富肽作为人类蛋白酶体活性的灵活变构调节剂。
J Med Chem. 2019 Jan 10;62(1):359-370. doi: 10.1021/acs.jmedchem.8b01025. Epub 2018 Dec 3.
8
PA28γ: New Insights on an Ancient Proteasome Activator.PA28γ:古老蛋白酶体激活剂的新见解。
Biomolecules. 2021 Feb 5;11(2):228. doi: 10.3390/biom11020228.
9
Atomic force microscopy of proteasome assemblies.蛋白酶体组装体的原子力显微镜观察
Methods Mol Biol. 2011;736:117-32. doi: 10.1007/978-1-61779-105-5_9.
10
Modeling the in vitro 20S proteasome activity: the effect of PA28-alphabeta and of the sequence and length of polypeptides on the degradation kinetics.体外20S蛋白酶体活性建模:PA28αβ以及多肽序列和长度对降解动力学的影响。
J Mol Biol. 2008 Apr 11;377(5):1607-17. doi: 10.1016/j.jmb.2008.01.086. Epub 2008 Feb 8.

引用本文的文献

1
Genetic and pharmacologic proteasome augmentation ameliorates Alzheimer's-like pathology in mouse and fly APP overexpression models.遗传和药理学的蛋白酶体增强可改善 APP 过表达小鼠和果蝇阿尔茨海默病样病理。
Sci Adv. 2022 Jun 10;8(23):eabk2252. doi: 10.1126/sciadv.abk2252. Epub 2022 Jun 8.
2
Cooperative Binding of the Cationic Porphyrin Tris-T4 Enhances Catalytic Activity of 20S Proteasome Unveiling a Complex Distribution of Functional States.三-T4 阳离子卟啉的协同结合增强 20S 蛋白酶体的催化活性,揭示了功能状态的复杂分布。
Int J Mol Sci. 2020 Sep 29;21(19):7190. doi: 10.3390/ijms21197190.
3
Characterization of platinum(II) complexes exhibiting inhibitory activity against the 20S proteasome.

本文引用的文献

1
The program XEASY for computer-supported NMR spectral analysis of biological macromolecules.用于生物大分子的计算机支持的 NMR 光谱分析的 XEASY 程序。
J Biomol NMR. 1995 Jul;6(1):1-10. doi: 10.1007/BF00417486.
2
Structural models for interactions between the 20S proteasome and its PAN/19S activators.20S 蛋白酶体与其 PAN/19S 激活剂相互作用的结构模型。
J Biol Chem. 2010 Jan 1;285(1):13-7. doi: 10.1074/jbc.C109.070425. Epub 2009 Nov 4.
3
Conformational changes in salivary proline-rich protein 1 upon adsorption to calcium phosphate crystals.
对表现出针对20S蛋白酶体抑制活性的铂(II)配合物的表征。
R Soc Open Sci. 2020 Aug 19;7(8):200545. doi: 10.1098/rsos.200545. eCollection 2020 Aug.
4
New Peptide-Based Pharmacophore Activates 20S Proteasome.新型基于肽的药效团激活 20S 蛋白酶体。
Molecules. 2020 Mar 22;25(6):1439. doi: 10.3390/molecules25061439.
5
Cationic porphyrins are tunable gatekeepers of the 20S proteasome.阳离子卟啉是20S蛋白酶体的可调守门人。
Chem Sci. 2016 Feb 1;7(2):1286-1297. doi: 10.1039/c5sc03312h. Epub 2015 Nov 9.
6
Proteasome Activators, PA28 and PA28, Govern Development of Microvascular Injury in Diabetic Nephropathy and Retinopathy.蛋白酶体激活剂PA28和PA26调控糖尿病肾病和视网膜病变中微血管损伤的发展。
Int J Nephrol. 2016;2016:3846573. doi: 10.1155/2016/3846573. Epub 2016 Oct 18.
7
Interplay between Structure and Charge as a Key to Allosteric Modulation of Human 20S Proteasome by the Basic Fragment of HIV-1 Tat Protein.结构与电荷之间的相互作用是HIV-1 Tat蛋白碱性片段对人20S蛋白酶体变构调节的关键。
PLoS One. 2015 Nov 17;10(11):e0143038. doi: 10.1371/journal.pone.0143038. eCollection 2015.
8
Sequence-specific alterations of epitope production by HIV protease inhibitors.HIV 蛋白酶抑制剂对表位产生的序列特异性改变。
J Immunol. 2014 Apr 15;192(8):3496-506. doi: 10.4049/jimmunol.1302805. Epub 2014 Mar 10.
9
Inhibition of human and yeast 20S proteasome by analogues of trypsin inhibitor SFTI-1.胰蛋白酶抑制剂SFTI-1类似物对人和酵母20S蛋白酶体的抑制作用
PLoS One. 2014 Feb 25;9(2):e89465. doi: 10.1371/journal.pone.0089465. eCollection 2014.
10
Harnessing proteasome dynamics and allostery in drug design.在药物设计中利用蛋白酶体动力学和变构作用。
Antioxid Redox Signal. 2014 Dec 10;21(17):2286-301. doi: 10.1089/ars.2013.5816. Epub 2014 Feb 21.
富含脯氨酸的唾液蛋白1吸附到磷酸钙晶体上后的构象变化。
Langmuir. 2007 Oct 23;23(22):11200-5. doi: 10.1021/la7013978. Epub 2007 Sep 20.
4
20S proteasome and its inhibitors: crystallographic knowledge for drug development.20S蛋白酶体及其抑制剂:药物研发的晶体学知识
Chem Rev. 2007 Mar;107(3):687-717. doi: 10.1021/cr0502504. Epub 2007 Feb 23.
5
Allosteric regulators of the proteasome: potential drugs and a novel approach for drug design.蛋白酶体的变构调节剂:潜在药物及药物设计的新方法。
Curr Med Chem. 2006;13(2):155-65. doi: 10.2174/092986706775197926.
6
Regulated protein degradation.受调控的蛋白质降解
Trends Biochem Sci. 2005 Jun;30(6):283-6. doi: 10.1016/j.tibs.2005.04.005.
7
The 1.9 A structure of a proteasome-11S activator complex and implications for proteasome-PAN/PA700 interactions.蛋白酶体-11S激活剂复合物的1.9埃结构及其对蛋白酶体-PAN/PA700相互作用的影响
Mol Cell. 2005 May 27;18(5):589-99. doi: 10.1016/j.molcel.2005.04.016.
8
Molecular machines for protein degradation.用于蛋白质降解的分子机器。
Chembiochem. 2005 Feb;6(2):222-56. doi: 10.1002/cbic.200400313.
9
Mobilizing the proteolytic machine: cell biological roles of proteasome activators and inhibitors.激活蛋白水解机器:蛋白酶体激活剂和抑制剂的细胞生物学作用
Trends Cell Biol. 2005 Jan;15(1):27-33. doi: 10.1016/j.tcb.2004.11.003.
10
The polyproline II conformation in short alanine peptides is noncooperative.短丙氨酸肽中的多聚脯氨酸II构象是非协同性的。
Proc Natl Acad Sci U S A. 2004 Oct 26;101(43):15352-7. doi: 10.1073/pnas.0406657101. Epub 2004 Oct 15.